A Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Effects of Esomeprazole 40 mg bid on the Signs and Symptoms of Chronic Posterior Laryngitis in Patients with Suspected Laryngopharyngeal Reflux

Study identifier:291

ClinicalTrials.gov identifier:N/A

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

A Multicenter, Double-blind, Placebo-controlled Study to Evaluate the Effects of Esomeprazole 40 mg bid on the Signs and Symptoms of Chronic Posterior Laryngitis in Patients with Suspected Laryngopharyngeal Reflux

Medical condition

gastrointestinal diseases

Phase

N/A

Healthy volunteers

-

Study drug

-

Sex

-

Actual Enrollment

-

Study type

Interventional

Age

-

Date

Study Start Date: 01 Jan 1971
Primary Completion Date: -
Study Completion Date: -

Study design

Allocation: -
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2013 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria